27 Feb 2020


Authors: Peter Richardson, Ivan Griffin, Catherine Tucker, Dan Smith, Olly Oechsle, Anne Phelan, Justin Stebbing


Earlier this month we published research in The Lancet in which we identified and analysed data on several drugs, of which baricitinib was the most promising. Baricitinib is an already approved drug which is predicted to inhibit the COVID19 infection of human cells. To take this work further in a short timescale, a necessity in a global health emergency, we re-examined the affinity and selectivity of all the approved drugs in our knowledge graph to identify those with both anti-viral and anti-inflammatory properties. This research found combinations of baricitinib with the directly acting antivirals currently being used in the COVID-19 outbreak could reduce viral infectivity, virus replication and also the aberrant host inflammatory response. The use of an AI-driven knowledge graph facilitated this rapid response.

Back to publications

Latest publications

09 Oct 2023
Learning the kernel for rare variant genetic association test
Read more
24 Aug 2023
Associating biological context with protein-protein interactions through text mining at PubMed scale
Read more
07 Dec 2022
NeurIPS 2022
sEHR-CE: Language modelling of structured EHR data for efficient and generalizable patient cohort expansion
Read more